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h peBACKGROUND AND PURPOSE
Small conductance calcium-activated potassium (KCa2.x) channels have a widely accepted canonical function in regulating cel-
lular excitability. In this study, we address a potential non-canonical function of KCa2.x channels in breast cancer cell survival,
using in vitro models.
EXPERIMENTAL APPROACH
The expression of all KCa2.x channel isoforms was initially probed using RT-PCR, Western blotting and microarray analysis in ﬁve
widely studied breast cancer cell lines. In order to assess the effect of pharmacological blockade and siRNA-mediated knockdown
of KCa2.x channels on these cell lines, we utilized MTS proliferation assays and also followed the corresponding expression of
apoptotic markers.
KEY RESULTS
All of the breast cancer cell lines, regardless of their lineage or endocrine responsiveness, were highly sensitive to KCa2.x channel
blockade. UCL1684 caused cytotoxicity, with LD50 values in the low nanomolar range, in all cell lines. The role of KCa2.x channels
was conﬁrmed using pharmacological inhibition and siRNA-mediated knockdown. This reduced cell viability and also reduced
expression of Bcl-2 but increased expression of active caspase-7 and caspase-9. Complementary to these results, a variety of cell
lines can be protected from apoptosis induced by staurosporine using the KCa2.x channel activator CyPPA.
CONCLUSIONS AND IMPLICATIONS
In addition to a well-established role for KCa2.x channels in migration, blockade of these channels was potently cytotoxic in breast
cancer cell lines, pointing to modulation of KCa2.x channels as a potential therapeutic approach to breast cancer.Abbreviations
AHP, afterhyperpolarization; FasR, faslodex-resistant cell line; KCa2.x/SK channels, small conductance Ca
2+-activated
potassium channels; No-RT, No reverse transcriptase; SK2-L, KCNN2 channel long isoform; SK2-S, KCNN2 channel short
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SK channels or small conductance calcium-activated K+ chan-
nels (KCa2.x) are a family of K
+ channels gated exclusively in
response to rises in intracellular Ca2+ (Kohler et al., 1996;
Adelman et al., 2012). The family consists of three channels
(KCa2.1, KCa2.2, KCa2.3) with the pore forming subunit being
encoded by the genes KCNN1–KCNN3 and a closely related
channel KCNN4 also known as the intermediate conductance
Ca2+-activated K+ channel (SK4, IK and KCa3.1). The SK (KCa2.x)
channels do not have inherent Ca2+ binding domains and
instead utilize calmodulin as their high afﬁnity Ca2+ sensor
(Xia et al., 1998; Maylie et al., 2004; Li et al., 2009; Halling
et al., 2014). The Ca2+ sensitivity of the channel is then
tightly regulated by the activity of a bound kinase (CK2)
and phosphatase (PP2A). The canonical role of KCa2.x chan-
nels in physiology is in regulating cellular excitability, and
to this end, these channels are widely expressed throughout
the CNS where they play fundamental roles in generation
of afterhyperpolarizations (AHPs), synaptic transmission
and potentially in the generation of synaptic plasticity (Bond
et al., 2004; Faber et al., 2005; Hammond et al., 2006; Faber
et al., 2008; Nanou et al., 2013). In addition to these canonical
roles it has become evident that KCa2.x channels, much like
other ion channels, have numerous non-canonical functions
that span both excitable and non-excitable cells (Pardo et al.,
1998; Henney et al., 2009; Huang et al., 2012; Pardo and
Stuhmer, 2014; Urrego et al., 2014). Importantly, many ion
channels have been implicated in processes related to cancer
cell survival, motility, development and progression
(Pedersen and Stock, 2013; Andersen et al., 2014; Pardo and
Stuhmer, 2014); in particular, expression of KCa2.3 channels
has been conclusively linked to breast cancer cell motility
and hence to metastases (Potier et al., 2006; Potier et al.,
2010; Girault et al., 2012; Chantome et al., 2013). Here, we ex-
plore the role of KCa2.x channels in ﬁve widely used breast
cancer cell lines, reﬂective of lineage and also endocrine resis-
tance (Holliday and Speirs, 2011), using pharmacological
modulators of KCa2.x channels to dissect the role of these
channels in cell survival. Considering the huge global healthburden that breast cancer represents, where globally only
lung cancer kills more women each year, it is desirable to
open as many potential therapeutic research avenues as
possible.
Here, we have shown that KCa2.x channels are expressed in
four breast cancer cell models comprising estrogen receptor pos-
itive (ER+), endocrine responsive luminal A and B lines MCF-7
and BT-474 respectively and MCF-7-derived endocrine-resistant
models, tamoxifen-resistant cell line (TamR) and faslodex-
resistant cell line (FasR),. Further, KCa2.3 channelswere expressed
in the commonly used estrogen receptor negative (ER) breast
cancer cell line, MDA-MB-231 cells. Pharmacological blockade
using low MW inhibitors and siRNA demonstrated that KCa2.x
channel knockdown was cytotoxic in not only breast cancer cell
lines of varying ER expression but also two endocrine-resistant
cell lines (TamR and FasR). Knockdown of KCa2.2 and KCa2.3
channels was accompanied by a considerable down-regulation
of the anti-apoptotic protein Bcl-2 and a corresponding rise in
the active cleaved form of caspase-7, one of the three main effec-
tor caspases and caspase-9. Thus, we suggest that KCa2.x channel
blockade provided a pro-apoptotic stimulus, likely to activate the
intrinsic pathway. This was complemented by our data illustrat-
ing that activation of KCa2.x channels markedly inhibited the
effects of an apoptosis inducer (staurosporine) in a number of
CNS-derived cell lines where the function of KCa2.x channels is
better understood. Thus, we suggest a paradigm where aberrant
activation of KCa2.x channels staves off cell death in breast
cancer cell lines. These results clearly not only illustrate and
compound the therapeutic potential of the blockade of KCa2.2
and KCa2.3 channels in primary and endocrine-resistant breast
cancer, but also the importance of KCa2.x channels in cellular life
and death decisions.Methods
Cell lines
Breast cancer cells were provided by the Breast Cancer Molec-
ular Pharmacology group at the School of Pharmacy and
SK channels in breast cancer BJPPharmaceutical Sciences, Cardiff University, UK. MCF-10a
normal mammary cells were cultured in DMEM/F-12
(11320-074, Life Technologies) supplemented with 5% Horse
serum, 10 μgmL1 insulin (I9278, Sigma), 2 μgmL1 epider-
mal growth factor (E9644, Sigma) and 0.5 μgmL1 hydrocor-
tisone (H0888, Sigma). MCF-7 cells were cultured in RPMI
medium (Phenol Red+) supplemented with 5% FBS. TamR
and FasR cells were previously derived by the Breast Cancer
Molecular Pharmacology group from wild-type MCF-7 cells
continually exposed to 100 nM 4-hydroxytamoxifen and
Fulvestrant through to acquisition of stable resistance after
18 and 27months respectively. These cells were maintained
in RPMI medium (Phenol Red) with 5% charcoal-stripped
FBS. BT-474 cells were grown in DMEM with 10% FBS. MDA-
MB-231 cells were grown in DMEM in a ratio 1:1 with F12 nu-
trient mixture with 10% FBS. All media was supplemented
with 2mM L-glutamine, 100UmL1 penicillin and
100 μgmL1 streptomycin, with cells being maintained at
37°C with 5% CO2.RT-PCR
RT-PCR was carried out to determine the expression of KCa2.x
and KCa3.x channels at the mRNA level. Negative controls
represented RT-PCR reactions without RT and are denoted as
‘No RT’ throughout. Primers used are shown in Table 1.Table 1
Primer sequences for all KCa channel targets in human and murine cell lines
Genes
Human β-actin Forward 5′-CCCA
Reverse 5′-AGGG
Human KCNN1 Forward 5′-TGGA
Reverse 5′-TTAG
Human KCNN2 Forward 5′-CAAG
Reverse 5′-CCGC
Human KCNN3 Forward 5′-TCCA
Reverse 5′-CTTG
Human KCNN4 Forward 5′-GAGA
Reverse 5′-ACGT
Mouse β-actin Forward 5′-TGTT
Reverse 5′-GGG
Mouse KCNN1 Forward 5′-GAAG
Reverse 5′-CCAT
Mouse KCNN2 Forward 5′-TCTG
Reverse 5′-CCAC
Mouse KCNN3 Forward 5′-ACTT
Reverse 5′-GGAA
Mouse KCNN4 Forward 5′-AAGC
Reverse 5′-CCGTWestern blots
Western blotting was carried out to determine expression of
KCa2.2-L, KCa2.2-S, KCa2.3, Bcl-2, full length and cleaved
caspase-7 and cleaved caspase-8 and caspase-9. Breast cancer
cell lines either untransfected or transfected with control
siRNA or siRNA related to KCa2.2, 2.3, were lysed, denatured
and protein quantiﬁed using the BCA assay. Equal quantities
of protein were loaded and separated by electrophoresis on
10% (w/v) SDS-PAGE gels at 120V for 90min. Proteins were
wet blotted on to methanol-activated Hybond PVDF (GE
healthcare, UK) membranes in ice-cold transfer buffer at
100V for 60min, blocked in 5% (w/v) dried skimmed milk
in TBS-Tween® 20 for 3 h at room temperature and probed
with rabbit polyclonal anti-KCa2.2 (long isoform) (1:1000)
(Abcam), rabbit polyclonal anti-KCa2.2 (short isoform)
(1:1000) (Abcam), rabbit polyclonal anti-KCa2.3 (1:1000)
(Abcam), rabbit monoclonal anti-Bcl-2 (1:1000) (Abcam),
rabbit monoclonal anti-caspase-7 full length and cleaved
(1:1000) (Abcam), rabbit anti-cleaved caspase-7 (1:1000) (Cell
Signalling Technology), mouse anti-GAPDH (1:50 000)
(Sigma-Aldrich) rabbit polyclonal anti-KCa2.1 (1:1000)
(Abcam), rabbit monoclonal anti-GAP-43 (1:1000) (Abcam),
cleaved caspase-8 (1:1000) (Cell Signalling Technology),
cleaved caspase-9 (1:1000) (Cell Signalling Technology) all
applied in 5% (w/v) dried skimmed milk and TBS-Tween 20®
mixture and incubated at 4°C overnight. The next day,.
Primers Amplicon (bp)
GCCATGTACGTTGCTA-3′ 126
CATACCCCTCGTAGATG-3′
CACTCAGCTCACCAAG-3′ 208
CCTGGTCGTTCAGCTT-3′
CAAACACTTTGGTGGA-3′ 249
TCAGCATTGTAAGTGA-3′
TTGGTTATGGGGACAT-3′ 180
GTGAGCTGAGTGTCCA-3′
GGCAGGCTGTTATTGC-3′ 215
GCTTCTCTGCCTTGTT-3′
ACCAACTGGGACGACA-3′ 165
GTGTTGAAGGTCTCAAA-3′
CTTGGGTGAACTGAGC-3′ 232
TAAGGAATCCCCAGGT-3′
ATTGCCAGAGTCATGC-3′ 250
ATTGCTCCAAGGAAGT-3′
CAACACCCGATTCGTC-3′ 191
AGGAACGTGATGGAGA-3′
ACACTCGAAGGAAGGA-3′ 215
CGATTCTCTTCTCCAG-3′
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secondary antibod++y diluted in 5% (w/v) dried skimmed
milk TBS-Tween 20®, for 60min at room temperature: Anti-
rabbit IgG (1:10 000) (Cell Signalling Technology: no. 7074).
After a series of washes, proteins were detected using the
ECL Plus Western blotting chemiluminescent detection sys-
tem (Pierce, UK), and signals were captured on Hyperﬁlm
ECL autoradiography ﬁlm (GE healthcare, UK) in a dark
room. The exposure times for the detection were the follow-
ing: KCa2.2-L, KCa2.2-S, KCa2.3, Bcl-2, GAP43, full length
and cleaved caspase-7, cleaved caspase-8, cleaved caspase-9
for 2min, 3min, 2min, 2min, 3–30min, 30 s, 3min and
3min respectively and 1min for GAPDH for each blot after
stripping and reprobing. Western blot results were semi-
quantiﬁed using ImageJ software following, as closely as pos-
sible, protocols set out by Gassmann et al., 2009 (Gassmann
et al., 2009). Firstly, images were converted to 8-bit grayscale
(256 gray shades), and rectangles were drawn (30% of the
lane width – tight as possible with respect to band height)
around each band and lanes were plotted. As pointed out in
Gassmann et al. (2009), background correction can actually
impair the densitometry values obtained when using ImageJ
software so none was undertaken in this study (Gassmann
et al., 2009). The peak heights of relevant bands were utilized
and compared with loading control (GAPDH). ImageJ enables
each peak to be labeled with its size, and then it can be
expressed as a percentage of the total size of all of the
highlighted peaks on the blot. Using the relative densities of
the loading controls, adjusted density values for protein of
interest were calculated, by dividing the density of each
sample by the loading control.Cell viability assays
Cells were seeded in triplicate into 96-well plates at a den-
sity of 8 × 103 cells per well. The cells were then exposed
to treatment with SK channel modulators for 72 h, each
day cells being refreshed with the relevant media for the
individual cell line supplemented with the compound of
interest. For the MTS assay, 40mg MTS powder reagent
(Promega, UK) was dissolved in 20mL PBS. This mixture
(2.5mL) was added to PMS (120 μL) to form an MTS–PMS
mix at a ratio of 20:1. The MTS–PMS mixture (20 μL) was
pipetted into each well (ratio, 1:5), protected from light,
and incubated for 3 h. Results were read in a LT-5000MS
ELISA plate reader where relative cell viability was measured
as a function of absorbance.siRNA transfection
siRNAwas purchased from Euroﬁns Genomics.
GFP control siRNA 5′-GGCUACGUCCAGGAGCGCACC-3′,
KCa2.2 siRNA 5′-GCAUUGGAGCACUUAAUAA-3′(Exon 3)
KCa2.3 siRNA 5′-UUGUUGUUAUGGUGAUAGA-3′(Exon1)
Cells were plated in 6-well plates seeded at a density of 20
× 104 cells per well and left for 24 h. siRNA (50 nM KCa2.2
siRNA in MCF-7 and BT-474 cells and 80 nM of KCa2.3 siRNA
in MDA-MB-231 cells) was incubated with Oligofectamine™
(Invitrogen Life Technologies) at room temperature in
OptiMEM for 15min. Cells were then incubated for 72 h.
Transfected cells were harvested from 6-well plates and4 British Journal of Pharmacology (2015) •• ••–••reseeded in 96-well plates for 72 h, each day cells being
refreshed with normal medium. Cell viability was then
determined using an MTS assay and protein expression of
the relevant KCa2.x channel, Bcl-2, caspase-7, caspase-8 and
caspase-9 was quantiﬁed.Microarray
A quantitative approach supplementary to PCR was
employed to explore relative expression of transcripts
encoding SK1-4 channels. The technique involves labelling
of an RNA sample and allowing hybridization with gene-
speciﬁc targets on an array (Affymetrix 1.0ST GeneChip
platform). RNAwas extracted by the Breast Cancer Molecular
Pharmacology group from triplicate preparations of three
different cell lines (MCF-7, TamR and FasR cells) at three
passage numbers. Array analysis was then carried out using
the Affymetrix GeneChips and the resultant expression data
for the SK channels of interest subsequently analysed using
commercial GENESIFTER software, considering heatmap proﬁle
and expression level (log2intensity).Data analysis
For cell viability assays, data are represented as a mean of
each group ± SEM normalized to control. GraphPad Prism
6 was used to analyze the data using either Student’s t-test
(densitometry data), one-way ANOVA or two-way ANOVA,
with either Dunnett’s or Tukey’s post hoc tests employed,
not including controls of normalized data. Data were
considered statistically signiﬁcant when P < 0.05. If a more
stringent statistical threshold is set, it is noted in the ﬁgure
legend. 95% conﬁdence intervals are displayed where
appropriate.Materials
Pharmacological modulators of KCa2.x and KCa3.x channels
were purchased from Tocris Bioscience; CyPPA (Cat. no. 2953),
UCL1684 (Cat. no. 1310) and NS6180 (Cat. no. 4864).
NS8593 (Cat. no. N2538) was purchased from Sigma-
Aldrich, UK.Results
KCa2.2, 2.3 channel expression and
modulation in breast cancer cell lines
First, we looked at the expression of all three KCa2.x and
KCa3.1 channels in three widely used breast cancer cell lines
of varying lineage, namely, MCF-7 (Luminal A: ER+,
HER2), BT-474 (Luminal B: ER+, HER+) and MDA-MB-231
cells (Claudin-low: ER-, HER2-)(Holliday and Speirs, 2011).
In the adenocarcinoma MCF-7 cells, KCa2.2 and KCa3.1
channels were both present at the mRNA level (Figure 1A),
and KCa2.2 channel expression was conﬁrmed at the pro-
tein level using Western blotting (Figure 1B and Supporting
Information Fig. S1). In fact two isoforms of the KCa2.2
channel were identiﬁed which are known to form
heteromultimeric channels; isoform a, which is a longer
Figure 1
Expression and pharmacological/siRNA-mediated modulation of KCa2.2 channels in MCF-7 cells. (A) RT-PCR illustrates the presence of KCa2.2
(249 bp) and KCa3.1 channels (215 bp). Negative control represents RT-PCR reactions without RT (No RT), and positive control is β-actin
(126 bp). (B) Western blot analysis of KCa2.2 expression demonstrating knockdown of both KCa2.2 long (L) and short (S) isoforms by siRNA and
no effect of control siRNA (GFP targeted). Relative expression to GAPDH was calculated using densitometry (Supporting Information Fig. S1).
(C) Dose–response curve illustrating the effect of UCL1684 (KCa2.x) and NS6180 (KCa3.1) on MCF-7 viability after treatment for 72 h (data points
represent mean ± SEM; n = 9). (D) Effect of pharmacological blockers UCL1684 (KCa2.x) and NS6180 (KCa3.1) on the expression of Bcl-2, full
length (FL) and cleaved (CL) form of caspase-7 and cleaved caspase-8 and caspase-9. (E) Effect of siRNA-mediated knockdown of KCa2.2 channels
on MCF-7 viability. * P < 0.01; signiﬁcantly different as indicated; n = 9. (F) Expression of Bcl-2 and full length (FL) and cleaved (CL) form of
caspase-7, caspase-8 and caspase-9 were determined after 72 h of exposure to KCa2.2 channel siRNA.
SK channels in breast cancer BJPisoform with a large N-terminal extension (SK2-L) and iso-
form b, a shorter variant (SK2-S) (Allen et al., 2011).
We then looked at whether MCF-7 cells were sensitive to
KCa2.x and KCa3.1 channel modulators (Figure 1C and
Supporting Information Fig. S2). While MCF-7 cells were rela-
tively insensitive to the KCa3.1 channel blocker NS6180 (LD50
>> 0.1μM), they were highly sensitive to the KCa2.x channel
blocker UCL1684 with an LD50 of 6.3 nM (4.9–8.1; 95% conﬁ-
dence interval, n = 9) (Figure 1C). In contrast, the KCa2 channel
activator CyPPA (5–30μM) (Hougaard et al., 2007) increased cellviability by up to ~60% (Supporting Information Fig. S2). This ef-
fect was accompanied by an increase in Bcl-2 levels and could be
completely abolishedby the additionofUCL1684 to blockKCa2.x
channels (Figure S2).
After pharmacological inhibition of KCa2.2 channels
using UCL1684, we observed a marked reduction in Bcl-2
expression (approx. 10-fold) and a corresponding rise in the
expression of caspase-7 (approx. ﬁvefold), one of the three
main effector caspases (Figure 1D and Supporting Informa-
tion Fig. S3). It is important to note that the caspase-7British Journal of Pharmacology (2015) •• ••–•• 5
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caspase-7 post-enzymic cleavage. In the control, the activated
caspase-7, as we would expect, was absent, but on treatment
with the KCa2.2 channel blocker, both full length and most im-
portantly cleaved caspase-7was increased (Figure 1D). To further
probe the potential mechanism of UCL1684, we looked at
cleaved caspase-8 (extrinsic apoptotic pathway) and caspase-9
(intrinsic apoptotic pathway). We did not observe an increase
in caspase-8 expression, but there was a marked rise in caspase-
9 levels (Figure 1D).
Interestingly, the effects of UCL1684 were mirrored
using siRNA-mediated knockdown of KCa2.2 channels in
MCF-7 cells, conﬁrmed using Western blotting (Figure 1B,
E and Supporting Information Fig. S1). We found that the
siRNA used was as potent at knocking down the SK2-LFigure 2
Expression and pharmacological/siRNA-mediated modulation of KCa2.2 ch
(249 bp) and KCa3.1 channels (215 bp). (B) Western blot analysis of KCa2.2
(L) and short (S) isoforms by siRNA and no effect of control siRNA. Relative e
(Supporting Information Fig. S1). (C) Dose–response curve illustrating th
represent mean ± SEM; n = 9. (D) Effect of pharmacological blockers UCL
caspase-8 and caspase-9. (E) Effect of siRNA-mediated knockdown of KCa2.
as indicated; n = 9. (F) Expression of Bcl-2, full length (FL) and cleaved (CL
exposure to KCa2.2 channel siRNA.
6 British Journal of Pharmacology (2015) •• ••–••(long) isoform as the SK2-S (short) isoform. Under these
conditions, there was again a vast reduction in Bcl-2 expression
(up to 25-fold) and a corresponding rise in the expression of
caspase-7 and caspase-9 (Figure 1F and Supporting
Information Fig. S1).
KCa2.2 channel expressionwas also conﬁrmed in another lu-
minal endocrine responsive cell line BT-474 (Figure 2A and B).
Again, these cells were very sensitive to UCL1684 with an
LD50 of 4.0nM (3.1–5.1; 95% conﬁdence interval, n = 9)
(Figure 2C). This treatment again seemed to activate the in-
trinsic pathway resulting in a rise in caspase-9 expression
(Figure 2D). These effects could be mimicked by siRNA-
mediated knockdown of KCa2.2 channels (Figure 2B and E).
The knockdown mediated by siRNA was accompanied by a
marked decrease in Bcl-2 and an up-regulation of caspase-7annels in BT-474 cells. (A) RT-PCR illustrates the presence of KCa2.2
channel expression demonstrating knockdown of both KCa2.2 long
xpression compared with GAPDH was calculated using densitometry
e effect of UCL1684 (KCa2.x) on BT-474 cell viability. Data points
1684 (KCa2.x) and NS6180 (KCa3.1 ) on the expression of cleaved
2 channels on BT-474 cell viability * P < 0.01; signiﬁcantly different
) form of caspase-7 and cleaved caspase-8 and caspase-9 after 72 h
SK channels in breast cancer BJPand caspase-9, identical to the effects seen in MCF-7 cells
(Figure 2F and Supporting Information Fig. S1).
In contrast, the claudin-low cell line MDA-MB-231 that is
ER and HER seemed not to express KCa2.2 channels but did
express KCa2.3 channels (Figure 3A and B). UCL1684 is slightly
more selective for KCa2.1 and KCa2.2 channels so, in addition,
we tested NS8593 (another generic KCa2.xchannel blocker) on
the growth ofMDA-MB-231 cells. Both demonstrated potent cy-
totoxicity with LD50 values of 6.1nM (4.8–7.7; 95% conﬁdence
interval, n = 9) and 813nM (626–1057; 95% conﬁdence interval,
n = 9) respectively over the time frame of the experiments
(Figure 3C andD). Furthermore, as in both the luminal cell lines
expressing KCa2.2 channels, siRNA-mediated knockdown of
KCa2.3 channels had a profound cytotoxic effect and caused a
decrease in Bcl-2 expression and an increase in cleaved
caspase-7 and caspase-9 expression (Figure 3E and F and
Supporting Information Fig. S1).
After seeing these potent effects of KCa2 channel inhibi-
tion on breast cancer cell lines, we looked at whether theFigure 3
Expression and pharmacological/siRNA-mediated modulation of KCa2.3 ch
KCa2.3 (180 bp) and KCa3.1 channels (215 bp). (B) Western blot analysis
and no effect of control siRNA. Relative expression was calculated using den
lustrating the effect of (C) NS8593 and (D) UCL1684 on MDA-MB-231
siRNA-mediated knockdown of KCa2.3 channels on MDA-MB-231 cell viabili
of Bcl-2, full length (FL) and cleaved (CL) form of caspase-7 and cleaved casp
siRNA.same could be seen in the non-cancerous mammary epithe-
lial cell line MCF-10A. We probed expression at the mRNA
level and the protein level, and no KCa2.x channel isoforms
could be detected (Figure 4A and B). Thus, unsurprisingly,
neither treatment with UCL1684 nor siRNA speciﬁc for
KCa2.2 or KCa2.3 channels had any effect on MCF-10A cell
viability (Figure 4C and D).Effect of KCa2.x channel blockers on
endocrine-resistant breast cancer cell lines
Next, we sought to decipher whether KCa2.x channels were
expressed and whether their blockade was as potently cyto-
toxic in two endocrine-resistant cell lines. TamR and FasR cell
lines were previously derived from MCF-7 cells which have
been treated continuously until they acquired resistance to
the endocrine agents, tamoxifen and faslodex respectively,
two widely used treatments for breast cancer (Knowlden
et al., 2003; Knowlden et al., 2005; Nicholson et al., 2005).annels in MDA-MB-231 cells. (A) RT-PCR illustrates the presence of
of KCa2.3 channel expression demonstrating knockdown by siRNA
sitometry (Supporting Information Fig. S1). Dose–response curve il-
cell viability. Data shown are means ± SEM; n = 9. (E) Effect of
ty. * P < 0.05; signiﬁcantly different as indicated; n = 9. (F) Expression
ase-8 and caspase-9 in response to 72 h exposure to KCa2.3 channel
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Figure 4
Expression and pharmacological/siRNA-mediatedmodulation of KCa2.x channels in the humanmammary epithelial cell line MCF-10A. (A) RT-PCR
illustrates a faint band for KCa2.1 (208 bp) and KCa3.1 channels (215 bp). Negative control represents RT-PCR reactions minus RT (No RT) and pos-
itive control is β-actin (126 bp). (B) Western blot analysis of KCa2.x channel expression demonstrates that although a faint PCR band is present
relating to the mRNA signal for KCa2.1 channels, they were not expressed at the protein level (comparison withMCF-7 andMDA-MB-231 cell lines
are shown). (C) Dose–response curve illustrating the effect of UCL1684 (KCa2.x) on MCF-10A viability after treatment for 72 h. Data shown are
means ± SEM; n = 9. (D) Effect of siRNA speciﬁc to KCa2.2 and KCa2.3 channels on cell viability of MCF-10A cells (n = 7).
BJP Z A Abdulkareem et al.TamR and FasR KCNN1–KCNN4 expression was probed using
PCR and Western blotting (Figure 5A and B). Both FasR and
TamR expressed KCa2.2 and KCa3.1 channels at the mRNAFigure 5
Expression and pharmacological modulation of KCa2.2 channels in the endoc
ence of KCa2.2 (249 bp) and KCa3.1 channels (215 bp) at the mRNA level in T
analysis of KCa2.2 channel expression at the protein level in MCF-7, TamR an
Genesifter Microarray heatmap illustrating an up-regulation (red) of KCa3.1 c
marginal down-regulation of KCa2.2 channels in FasR and KCa3.1 in TamR
UCL1684 on TamR and FasR cell lines. Data shown are means ± SEM; n = 9
8 British Journal of Pharmacology (2015) •• ••–••level with expression of KCa2.2 channels being conﬁrmed in
both using Western blotting. We also undertook microarray
analysis on relative expression of KCa2.x na d KCa3.x channelsrine-resistant cell lines TamR and FasR. (A) RT-PCR illustrates the pres-
amR cells (upper panel) and FasR cells (lower panel). (B) Western blot
d FasR cells, looking at both KCa2.2-S and the KCa2.2-L isoforms. (C)
hannels in FasR cells compared with MCF-7 cells; P< 0.01. There was
cells; P > 0.05. (D) Dose–response curve illustrating the effect of
.
SK channels in breast cancer BJPin TamR and FasR cell lines comparing them with the expres-
sion seen in the parental cell line, MCF-7 (Figure 5C). This
analysis conﬁrmed the expression of KCa2.2 and KCa3.1 chan-
nels in MCF-7 and the resistant models (KCNN2 and KCNN4
respectively; Genesifter log2intensity>7), with no expression
of either KCNN1 or KCNN3. There was a marked increase
(fourfold) in the expression of KCa3.1 channels in FasR com-
pared with MCF-7 cells apparent on the heatmaps (P-value
< 0.01), but no signiﬁcant change in mRNA expression was
seen for any KCa2.x isoform versus MCF-7 (Figure 5C). Both
resistant cell lines exhibited high sensitivity to the KCa2.x
channel blocker UCL1684 with an LD50 of 3.9 nM (2.9–5.2;
95% conﬁdence interval, n = 9) for FasR cells and 5.8 nM
(4.8–6.9; 95% conﬁdence interval, n = 9) for TamR cells
(Figure 5D).Are KCa2.x channel blockers generally
cytotoxic?
As a comparison, we tested the KCa2.x channel blockers on
other cell lines, both expressing and not expressing KCa2.x
channels, in order to determine how speciﬁc these observed
effects on breast cancer lines might be. Here, we used CNS-
derived cell lines as the functional role of KCa2.x channels
in these cell types in vivo have been widely probed. Again,
we probed KCa2.x channel expression at the mRNA level
and protein level and conﬁrmed the presence of a neuronal
marker in differentiated SH-SY5Y cells, namely, GAP-43
(Figure 6 and Supporting Information Fig. S4). Neither
UCL1684 (10 nM) nor NS8593 (1 μM) affected the cell
viability of SH-SY5Y (neuronal – KCa2.1 and KCa2.3) cells or
MOG-G-UVW (astrocytic – KCa3.1) cells (Figure 6A–C and
Supporting Information Fig. S4). They were also without ef-
fect on a murine striatal cell line STHdh, which is the controlFigure 6
Expression of KCa2.\ in CNS-derived cell lines. (A) Expression of KCa2.1 chan
KCa2.3 channels in differentiated and undifferentiated SH-SY5Y. (C) Conﬁrm
treatment using GAP-43 as a neuronal marker. (D) Expression of KCa2.2 cha
striatal neurons (STHdhQ111/Hdh+). (E) KCa2.3 channel expression in wild-tyline for a murine model of Huntington’s disease (Trettel et al.,
2000). These cells were chosen as striatal cells from the wild-
type, heterozygous and homozygous mice in this particular
model display differential expression of KCa2.x channels, which
in itself is noteworthy (Figure 6D and E and Supporting
Information Fig. S4). Of speciﬁc relevance is that in the striatal
neurons of homozygous mice (STHdhQ111/Q111) displaying the
Huntington-like phenotype, we could only identify KCa2.1
(SK1) channels, which cannot form functional homomeric
channels in mouse or rat (Benton et al., 2003; Adelman et al.,
2012). This means homozygous mice showing the
Huntington’s phenotypewouldmost likely bewithout AHP cur-
rents driven by KCa2.x channels releasing the ‘braking inﬂu-
ence’ on neuronal excitability that they confer. In fact, this is
functionally what is seen in another mouse model presenting
with a Huntington-like phenotype (Moriguchi et al., 2006). In
this model, the expression of KCa2.x channels is not lost, but
an apamin-sensitive AHP current is functionally lost. This initial
expression analysis is the subject of an ongoing study. Although
this is obviously not an exhaustive cytotoxicity screen, it does
illustrate some speciﬁcity of the effects of UCL1684 and
NS8593 on cancer cells.Activation of KCa2.x channels ameliorates cell
death induced by staurosporine
Staurosporine is a natural product isolated from Streptomyces
staurosporeus, which is widely used to induce apoptosis
(Nakagawa et al., 2000; Belmokhtar et al., 2001; Dong et al.,
2001; Marti et al., 2006; Sullivan et al., 2008). So we used
CNS-derived cell lines where cell proliferation was insensitive
to KCa2.x channel blockade to probe the question, can activa-
tion of these channels ameliorate the cellular response to an
apoptotic stimulus? To this end, we treated three cell linesnels in differentiated and undifferentiated SH-SY5Y. (B) Expression of
ation that SH-SY5Y cells are differentiated in response to retinoic acid
nnels, both long and short isoforms, in heterozygous mutant murine
pe murine striatal neurons STHdh.
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them with the KCa2.x channel activator CyPPA. The response
of these cell lines to staurosporine alone is consistent with
previous reports (LD50 ~10–100 nM for 24 h treatment)
(Sullivan et al., 2008; Sodja et al., 2014). The co-treatment
with CyPPA then increased cell viability by up to 30% when
compared with staurosporine alone (Figure 7A–C). This
clearly illustrates that in addition to KCa2.x channel knock-
down providing a pro-apoptotic signal in breast cancer cell
lines, activation of these channels can ameliorate the effects
of an apoptotic stimulus. To ensure these effects were not sim-
ply due to an increase in viability as we observed over a 72 h
period, we tested whether CyPPA alone affected cell viability
over 24 h. CyPPA ( 50 μM) did not affect cell viability on any
of the CNS-derived cell lines (Figure 7A–C). Furthermore, we
showed that the effects of CyPPA on staurosporine-induced
cell death was abolished by the application of the KCa2.x
channel blocker UCL1684 at a dose comparable with the
LD50 doses in cancer cells (Figure 7D and E).Discussion
We examined here the cytotoxicity resulting from modula-
tion of KCa2.x channels in breast cancer cell lines. Previously,
KCa2.x channels have been implicated in cancer cell migra-
tion (Potier et al., 2006; Potier et al., 2010) and in line with
other data, the expression proﬁle of KCa2.2 and KCa2.3 chan-
nels demonstrated here mirrors the fact that MDA-MB-231
cells (expressing KCa2.3 channels) are more motile than
MCF-7 cells, which lack these channels (Krueger et al., 2001;
Potier et al., 2006; Potier et al., 2010; Girault et al., 2012).
Our results clearly show that three widely used breast cancer
cell lines that cumulatively reﬂect key breast cancer subtypes
(luminal A, B, claudin low; ER+ and ER) not only express
KCa2.x channels but also are exquisitely sensitive to their
blockade, with the compound UCL1684 causing decreases
in cell viability with LD50 values in the nanomolar range
(~5 nM). These effects could be reproduced in each of these
cell lines using siRNA-mediated knockdown of the relevant
KCa2.x channels. Despite a lack of complete siRNA-mediated
knockdown of KCa2.x channel expression in MCF-7 and
MDA-MB-231 cells, substantial effects were still seen on cell
viability. Furthermore, both siRNA-mediated knockdown
and pharmacological blockade were accompanied by a fall
in the anti-apoptotic protein Bcl-2 and a rise in the active
form of the effector caspase-7 and caspase-9. From this, we
suggest that KCa2.x channel blockade is providing a pro-
apoptotic signal in particular, activating the intrinsic path-
way (caspase-9 is activated during the intrinsic pathway). To
date, there is much evidence of a role for K+ channels in pro-
liferation and cell cycle progression (Huang et al., 2012;
Urrego et al., 2014). Here, we assume that these breast cancer
cells are ‘high-jacking’ KCa2.x channels to drive growth by
resisting apoptosis which is largely supported by the fact that
the KCa2.x channel activator CyPPA, which acts by increasing
the channel sensitivity to intracellular Ca2+, actually in-
creased cell viability in both cell lines tested over 72 h with
a corresponding rise in Bcl-2 levels (MCF-7 and MDA-
MB-231) (Hougaard et al., 2007). CyPPA has previously been
shown not to affect cell viability in microglia, but this was
only up to 48 h treatment, and we also show similar data10 British Journal of Pharmacology (2015) •• ••–••when we treat CNS-derived cells over a shorter time frame
(Figure 7), that is, no increase in cell viability (Dolga et al.,
2012).
Previous reports have suggested that breast cancer cell
line growth is not sensitive to apamin, another KCa2.x
channel blocker. So an obvious question is why the sensi-
tivity to UCL1684 and NS8593 but not apamin? For exam-
ple, Potier et al. (2006) showed that apamin (100 nM) did
not affect viability in MDA-MB-435 cells (Potier et al.,
2006) over a 24 h period. However, in our experiments, we
challenged cells over 72 h. In addition, KCa2.2 channel ex-
pression in melanoma cells is increased under hypoxic con-
ditions, and it is only then that these cells become sensitive
to apamin (Tajima et al., 2006). So a lack of sensitivity of
cell viability to apamin may also be related to relative ex-
pression levels. Finally, both UCL1684 and NS8593 are
low MW inhibitors, whereas apamin is a peptide. Thus,
the effects seen may be related to their relative membrane
permeability and hence to KCa2.2 channel blockade at the
mitochondrial level rather than at the plasma membrane.
With this in mind, it is important to note that there is a
burgeoning literature on the role of mitochondrial KCa2.x
channels in cell physiology (Dolga et al., 2011; Dolga and
Culmsee, 2012; Dolga et al., 2013; Dolga et al., 2014;
Richter et al., 2015). Mitochondrial membrane potential is
linked to the intrinsic apoptotic pathway, and thus, modu-
lation of KCa2.x channels in mitochondria may explain
the effects seen in the cancer cell lines.
Blockade of KCa2.x channels not only reduced cell viabil-
ity in the endocrine responsive luminal cell lines but also
reduced viability in a dose-dependent manner in two
endocrine-resistant models (TamR and FasR). The KCa2.x
channel blocker UCL1684 LD50 values again were in the low
nanomolar range, with FasR cells being slightly more sensi-
tive to UCL1684 than other cell lines. This is perhaps in part
due to a slightly lower expression level of KCa2.2 channels,
compared with both MCF-7 and TamR cells (although
microarray data did not show a signiﬁcant difference in
mRNA levels).
Furthermore, when tested at two to four times the LD50
for breast cancer cell lines on ﬁve other cell lines of central
nervous system origin, the same KCa2 channel blockers were
without effect. In addition, UCL1684 did not affect the non-
cancerous mammary cell line MCF-10A. From this, we sug-
gest that the cytotoxic effects seen in breast cancer cells are
not widespread and may be suggestive of aberrant or special-
ized function of KCa2.x channels in breast cancer cell lines.
We went further using these cells, which were insensitive to
KCa2.x channel blockade. In reverse to what is seen in breast
cancer lines, we wanted to know whether KCa2.x channel ac-
tivation could ameliorate the effects of an apoptosis inducer,
staurosporine. Interestingly, and totally internally consistent
with our results, CyPPA treatment prevented the reduction in
viability in three cell lines of CNS origin caused by
staurosporine. The protection afforded by CyPPA was
abolished by the addition of a KCa2.2 channel blocker. All of
which clearly indicated a role of KCa2.x channels in cellular
life and death decisions.
In conclusion, we have clearly demonstrated the cytotox-
icity of KCa2.x channel knockdown in breast cancer cell lines.
The marked sensitivity of these cell lines, spanning breast
Figure 7
Effect of KCa2.x channel activation on cell death induced by staurosporine. (A) Effect of KCa2.x channel activation (with CyPPA) in the presence of
staurosporine (30 nM) on wild-type murine striatal neurons (STHdh) over 24 h (left panel). (B) Effect of KCa2.x channel activation (CyPPA) in the
presence of staurosporine (30 nM) on heterozygous mutant murine striatal neurons (STHdhQ111/Hdh+) from a murine model of Huntington’s dis-
ease over 24 h (left panel). (C) Effect of KCa2.x channel activation (CyPPA) in the presence of staurosporine (100 nM) on differentiated SH-SY5Y
cells over 24 h (left panel). CyPPA treatment alone does not affect cell viability in any of the cell lines over this time frame (right panels). Data points
represent mean ± SEM; n = 6. * P <0.05, signiﬁcant difference from staurosporine treatment alone. (D) Effect of UCL1684 on CyPPA-mediated
rescue of wild-type murine striatal neurons (STHdh) cells from staurosporine treatment. UCL1684-treated cells were not statistically different from
staurosporine alone; n = 7–9; two-way ANOVA – Tukey’s HSD. (D) Effect of UCL1684 on CyPPA-mediated rescue of heterozygous murine striatal
neurons (STHdhQ111/Hdh+) cells from staurosporine treatment. UCL1684-treated cells were not statistically different from staurosporine alone;
n = 7–9; two-way ANOVA – Tukey’s HSD.
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BJP Z A Abdulkareem et al.cancer subtypes and also both endocrine responsive and
endocrine-resistant models, overlap perfectly with the IC50
values previously reported for these KCa2.x channel blockers
(Dunn, 1999; Strobaek et al., 2006). Such KCa2.x channel
knockdown most likely provides a pro-apoptotic signal, as
siRNA-mediated knockdown and pharmacological inhibition
were accompanied by a decrease in Bcl-2 expression and a rise
in full length and cleaved active caspase-7 and cleaved
caspase-9 expression. Furthermore, activation of KCa2.x
channels reduced the effect of an apoptosis inducer,
staurosporine, on three CNS-derived cell lines, an effect that
could be reversed by blockade of these channels. While we
should be mindful of the complex heterogeneity of clinical
breast cancer, this provides clear, strong evidence that low
MW inhibitors of KCa2.x channels may represent a novel
therapeutic avenue in the treatment of primary ER+ and,
more importantly, ER and acquired endocrine-resistant
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